Emergent Biosolutions secures up to 22.3 million dollar order from U.S. Department of War

Emergent Biosolutions secures up to 22.3 million dollar order from U.S. Department of War
Emergent wins 22.3 million dollar deal

Emergent Biosolutions announced it has received a modification exercising an option period under its existing delivery order with the U.S. Department of War, valued at up to 22.3 million dollars.

The company stated that the first delivery in this arrangement is valued at approximately 7.4 million dollars. This contract covers the supply of a medical countermeasure for the department.

Emergent Biosolutions is scheduled to host its Q3 2026 earnings call on November 2 for investors and stakeholders. The company's recent engagements with government agencies have focused on supplying medical countermeasures. Updates on contract activity and financial results are expected during these upcoming disclosures.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.